相关实验视频

Updated: Jul 31, 2026

A Middle Cerebral Artery Occlusion Technique for Inducing Post-stroke Depression in Rats

A Middle Cerebral Artery Occlusion Technique for Inducing Post-stroke Depression in Rats

Published on: May 22, 2019

中国郊区中风患者中与药物相关的问题及其决定因素:基于PCNE的分析与有针对性的举措

Ying Liu¹, Mingfen Wu², Jing Zhao¹

¹Department of Pharmacy, Beijing Huairou Hospital, Capital Medical University Huairou Teaching Hospital, Beijing, China.

Frontiers in public health

|March 9, 2026

概括

与药物相关的问题在中国中风幸存者中很常见. 酒精使用和饮食等可改变的因素显著增加了风险,突出了药剂师干预改善药物管理的必要性.

科学领域:

药理学药理学是指药理学的学科.
公共卫生公共卫生
老年学是指老年学的学科.

背景情况:

脑卒中在中国是一个重大的公共卫生挑战.
对中风幸存者的长期药物治疗通常会导致与药物相关的问题 (DRPs).
了解DRP的决定因素对于改善这一群体的合理药物使用至关重要.

研究的目的:

在北京郊区社区住宿中风患者中识别与DRP相关的因素.
为优化药物管理和二次预防提供有针对性的干预信息.

主要方法:

481名中风患者的横截面研究 (2022年8月 - 2024年12月).
药剂师进行面对面的采访,以收集患者数据.
使用欧洲药物护理网络 (PCNE) 分类系统 (V9.1) 识别的药物药物处理程序 (DRP) (V9.1).
统计分析包括千平方测试和多变量逻辑回归.

主要成果:

确定了482个DRP,治疗效率低于最佳是常见的.
与患者相关的因素占主导地位,包括故意使用不足和错误的剂量.
酒精消费,糖尿病,抑郁/焦虑,以及高动物脂肪摄入量显著增加了DRP风险.
较低的收入,多药和较差的自我评估健康也与DRP有关.

结论:

在社区居住的中风幸存者中,DRP非常普遍.
可改变的行为和药物使用因素是DRP的关键驱动因素.
药剂师主导的干预措施,与基于PCNE的DRP识别相结合,可以优化药物管理并改善患者的治疗结果.

关键词:

这是PCNE分类.社区药房社区药房药物坚持药物坚持与毒品有关的问题.一次性中风中风中风中风中风

更多相关视频

Motor Dual-Tasks for Gait Analysis and Evaluation in Post-Stroke Patients

Motor Dual-Tasks for Gait Analysis and Evaluation in Post-Stroke Patients

Published on: March 11, 2021

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients

Published on: December 16, 2022

相关概念视频

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).